Group 1 - The proposal regarding the cancellation of the supervisory board, changes to the company's registered capital, and amendments to the articles of association needs to be submitted to the company's second extraordinary general meeting of shareholders in 2025 for review [1] - The shareholders' meeting will authorize the board of directors to handle the changes to the registered capital and amendments to the articles of association, with further authorization to the chairman or other designated individuals for related business registration and filing matters [1] Group 2 - The announcement is made by the board of directors of Wuxi AppTec Co., Ltd. on September 3, 2025 [2]

Core Viewpoint - WuXi AppTec is restructuring its organization to clarify the roles and responsibilities of its domestic operating entities and holding platforms, which includes transferring 98.9% of the shares of Hualan Pharmaceutical held by its subsidiary Shanghai WuXi to a newly established wholly-owned subsidiary, WuXi Research [1][2] Group 1: Company Actions - The share transfer involves WuXi AppTec transferring its entire 98.9% stake in Hualan Pharmaceutical to WuXi Research, which will directly hold these shares post-transfer [1] - This share transfer is within the board's authority and does not require shareholder approval, nor does it constitute a related party transaction or a major asset restructuring as per regulations [1] Group 2: Industry Context - The global CDMO industry is shifting from "capacity competition" to "technology + efficiency competition," with Hualan Pharmaceutical needing to adapt to technological advancements and evolving customer demands [2] - The restructuring aims to integrate resources between WuXi Research and Hualan Pharmaceutical, facilitating seamless transitions from research demands to production, which is crucial for maintaining Hualan's competitive edge in the small molecule sector [2] Group 3: Financial Implications - The share transfer is an internal asset reconfiguration that does not involve cash transactions, thus it will not significantly impact WuXi AppTec's financial statements [2] - The restructuring is expected to enhance overall operational efficiency in the long term, potentially leading to positive financial performance [2][3] Group 4: Future Considerations - The specific plan and implementation timeline for the share transfer remain uncertain, pending the signing of relevant agreements and approvals from tax authorities and business registration [3]

Core Viewpoint - WuXi AppTec is transferring 98.9% of its shares in Shanghai Hualian Pharmaceutical Co., Ltd. to WuXi AppTec (Shanghai) Pharmaceutical Development Co., Ltd. to optimize its organizational structure and enhance operational efficiency [1][3]. Company Summary - The share transfer is an internal asset reconfiguration and does not involve cash transactions, thus it will not significantly impact WuXi AppTec's financial statements [2]. - The transfer will not change the scope of consolidated financial statements or affect the operational activities of Hualian Pharmaceutical, nor will it impact its profits and overall equity [2]. - The restructuring aims to clarify the roles and responsibilities between domestic operating entities and holding platforms, enhancing the focus on core business areas [3]. Industry Summary - The global pharmaceutical CDMO industry is shifting from "capacity competition" to "technology + efficiency" competition, necessitating that Hualian Pharmaceutical adapt to technological advancements and evolving customer demands [1]. - The restructuring allows Hualian Pharmaceutical to concentrate on small molecule drug production processes, improving its professional capabilities while leveraging WuXi AppTec's global network to meet regional compliance and cost requirements [4]. - The specific implementation of the share transfer remains uncertain, pending the signing of relevant agreements and approvals from tax authorities and business registration [4].

Group 1 - The core point of the article is that WuXi AppTec announced the approval of several resolutions during its board meeting, including the cancellation of the supervisory board, changes to the company's registered capital, and amendments to the company's articles of association [2] Group 2 - The announcement was made on the evening of September 2, indicating a significant corporate governance change [2] - The resolutions will also involve the handling of business registration changes [2]

证券日报网讯 9月2日晚间，药明康德发布公告称，公司将于2025年9月23日召开2025年第二次临时股东 大会。本次股东大会将审议《关于取消监事会、变更公司注册资本、修改公司章程并办理工商变更登记 的议案》等多项议案。 （编辑 任世碧） ...

Core Insights - The total trading volume of the Shanghai and Shenzhen Stock Connect reached 367.08 billion, with WuXi AppTec and Zhongji Xuchuang leading in individual stock trading volume [1][2] - The banking sector saw the highest net inflow of funds, indicating strong investor interest [5][6] - The Hong Kong Dividend ETF (513690) experienced a significant trading volume increase of 256% compared to the previous day [11] Trading Volume Summary - The total trading amount for the Shanghai Stock Connect was 167.40 billion, while the Shenzhen Stock Connect totaled 199.68 billion [2] - WuXi AppTec topped the Shanghai Stock Connect with a trading volume of 37.28 billion, followed by Kweichow Moutai at 30.04 billion [3] - Zhongji Xuchuang led the Shenzhen Stock Connect with a trading volume of 55.10 billion, followed by Xinyi Technology at 42.81 billion [4] Sector Performance - The banking sector had a net inflow of 31.48 billion, making it the top-performing sector [6] - Other sectors with notable performance included precious metals, robotics, and oil, while sectors like CPO, cross-border payments, PCB, and semiconductors faced declines [5] Individual Stock Activity - Major inflows were seen in stocks like Jilun Intelligent with a net inflow of 12.01 billion and Industrial and Commercial Bank with 10.00 billion [8] - Conversely, significant outflows were recorded for stocks such as Xinyi Technology with a net outflow of 33.83 billion and Zhongji Xuchuang with 16.89 billion [9] ETF Trading Activity - The top ETF by trading volume was the Hong Kong Innovative Drug ETF (513120) with 142.73 billion, followed by the Hong Kong Securities ETF (513090) at 125.89 billion [10] - The Hong Kong Dividend ETF (513690) saw a remarkable increase in trading volume, ranking first in percentage growth at 256% [11] Futures Positioning - All four major futures contracts saw an increase in long positions, with the IC contract showing a particularly significant increase compared to short positions [12] Institutional Activity - Institutional buying was notable in stocks like Liou Co. with 2.22 billion and Jilun Intelligent with over 900 million [14] - Conversely, stocks like Jingwang Electronics and Innovation Medical faced substantial selling from institutions, with outflows of 4.12 billion and 2.16 billion respectively [15]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年9月2日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 无锡药明康德新药开发股份有限公司 董事会议事规则 董事会议事规则 第一章 总则 第一条 为了进一步规范无锡药明康德新药开发股份有限公司（以下简称 "公司"）董事会（以下简称"董事会"）的议事方 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 李革博士 香港，2025年9月2日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 无锡药明康德新药开发股份有限公司 股东会议事规则 （2025 年修订） （於中華人民共和國註冊成立的股份有限公司） 无锡药明康德新药开发股份有限公司 股东会议事规则 第一章 总则 第一条 为进一步明确无锡药明康德新药开发股份有限公司（以 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 无锡药明康德新药开发股份有限公司 银行间债券市场非金融企业 债务融资工具信息披露管理制度 （2025年修订） 无锡药明康德新药开发股份有限公司 银行间债券市场非金融企业 债务融资工具信息披露管理制度 第一章 总则 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年9月2日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年9月2日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 无锡药明康德新药开发股份有限公司 投资者关系管理办法 （2025 年修订） 投资者关系管理办法 第一章 总则 第一条 为加强对无锡药明康德新药开发股份有限公司（以下简称"公司"）与 投资者和潜 ...